JP2020521491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521491A5 JP2020521491A5 JP2019566236A JP2019566236A JP2020521491A5 JP 2020521491 A5 JP2020521491 A5 JP 2020521491A5 JP 2019566236 A JP2019566236 A JP 2019566236A JP 2019566236 A JP2019566236 A JP 2019566236A JP 2020521491 A5 JP2020521491 A5 JP 2020521491A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- oligonucleotide
- nucleoside
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 19
- 239000002777 nucleoside Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 10
- 239000000074 antisense oligonucleotide Substances 0.000 claims 9
- 238000012230 antisense oligonucleotides Methods 0.000 claims 9
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 7
- 125000003835 nucleoside group Chemical group 0.000 claims 7
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 208000008069 Geographic Atrophy Diseases 0.000 claims 3
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 3
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- -1 LNA nucleoside Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173964.2 | 2017-06-01 | ||
| EP17173964 | 2017-06-01 | ||
| EP17209407.0 | 2017-12-21 | ||
| EP17209535.8 | 2017-12-21 | ||
| EP17209535 | 2017-12-21 | ||
| EP17209407 | 2017-12-21 | ||
| PCT/EP2018/064221 WO2018220034A1 (en) | 2017-06-01 | 2018-05-30 | Antisense oligonucleotides for modulating htra1 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521491A JP2020521491A (ja) | 2020-07-27 |
| JP2020521491A5 true JP2020521491A5 (https=) | 2021-07-26 |
| JP7169995B2 JP7169995B2 (ja) | 2022-11-11 |
Family
ID=62245334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566236A Active JP7169995B2 (ja) | 2017-06-01 | 2018-05-30 | Ｈｔｒａ１発現を調節するためのアンチセンスオリゴヌクレオチド |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190055564A1 (https=) |
| EP (1) | EP3630976A1 (https=) |
| JP (1) | JP7169995B2 (https=) |
| KR (1) | KR20200015608A (https=) |
| CN (1) | CN110691849A (https=) |
| AU (1) | AU2018277219A1 (https=) |
| BR (1) | BR112019025290A2 (https=) |
| CA (1) | CA3062590A1 (https=) |
| CL (1) | CL2019003337A1 (https=) |
| CO (1) | CO2019013317A2 (https=) |
| CR (1) | CR20190543A (https=) |
| IL (1) | IL271039A (https=) |
| MA (1) | MA49278A (https=) |
| MX (1) | MX2019014187A (https=) |
| PE (1) | PE20191845A1 (https=) |
| PH (1) | PH12019502636A1 (https=) |
| RU (1) | RU2019143004A (https=) |
| TW (1) | TW201907008A (https=) |
| WO (1) | WO2018220034A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017289204A1 (en) | 2016-07-01 | 2019-01-17 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating HTRA1 expression |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| CN116507741A (zh) * | 2020-08-20 | 2023-07-28 | 基因组评论股份有限公司 | 年龄相关性黄斑变性诊断用生物标记物及其用途 |
| CA3199951A1 (en) * | 2020-10-30 | 2022-05-05 | Hideaki Hara | Gdf15 modulators for use in inhibiting ocular tissue fibrosis |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| WO2000008134A2 (en) * | 1998-08-03 | 2000-02-17 | Novartis Ag | HUMAN HtrA SERINE PROTEASE |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| EP2462937A1 (en) * | 2005-05-24 | 2012-06-13 | Isis Pharmaceuticals, Inc. | Modulation of LMW-PTPase Expression |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| AU2007277125B2 (en) * | 2006-07-26 | 2013-08-01 | Yale University | Diagnosis and treatment of age related macular degeneration |
| EP2081596A4 (en) * | 2006-10-06 | 2010-07-21 | Univ Utah Res Found | METHOD FOR THE DETECTION OF EYE DISEASES AND PATHOLOGICAL CONDITIONS AND TREATMENT THEREFOR |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| TW200911290A (en) | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
| CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| EP2217720A4 (en) * | 2007-11-01 | 2010-12-08 | Univ Iowa Res Found | RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| FR2965278B1 (fr) * | 2010-09-23 | 2014-10-10 | Univ Caen Basse Normandie | Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations |
| CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| US20190284621A1 (en) * | 2016-11-11 | 2019-09-19 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
-
2018
- 2018-05-29 US US15/991,326 patent/US20190055564A1/en not_active Abandoned
- 2018-05-30 PE PE2019002473A patent/PE20191845A1/es unknown
- 2018-05-30 MX MX2019014187A patent/MX2019014187A/es unknown
- 2018-05-30 WO PCT/EP2018/064221 patent/WO2018220034A1/en not_active Ceased
- 2018-05-30 CR CR20190543A patent/CR20190543A/es unknown
- 2018-05-30 BR BR112019025290-8A patent/BR112019025290A2/pt not_active Application Discontinuation
- 2018-05-30 CA CA3062590A patent/CA3062590A1/en not_active Abandoned
- 2018-05-30 MA MA049278A patent/MA49278A/fr unknown
- 2018-05-30 AU AU2018277219A patent/AU2018277219A1/en not_active Abandoned
- 2018-05-30 JP JP2019566236A patent/JP7169995B2/ja active Active
- 2018-05-30 RU RU2019143004A patent/RU2019143004A/ru unknown
- 2018-05-30 KR KR1020197038723A patent/KR20200015608A/ko not_active Withdrawn
- 2018-05-30 EP EP18727310.7A patent/EP3630976A1/en active Pending
- 2018-05-30 CN CN201880036053.5A patent/CN110691849A/zh active Pending
- 2018-05-31 TW TW107118609A patent/TW201907008A/zh unknown
-
2019
- 2019-10-28 US US16/665,317 patent/US20200157546A1/en not_active Abandoned
- 2019-11-20 CL CL2019003337A patent/CL2019003337A1/es unknown
- 2019-11-22 PH PH12019502636A patent/PH12019502636A1/en unknown
- 2019-11-27 CO CONC2019/0013317A patent/CO2019013317A2/es unknown
- 2019-11-28 IL IL271039A patent/IL271039A/en unknown
-
2021
- 2021-08-17 US US17/404,989 patent/US20220042022A1/en not_active Abandoned